Essential Focus Areas for Eli Lilly in the Present
Eli Lilly, a prominent player in the pharmaceutical industry, continues to make waves in the obesity treatment market with its innovative drugs. The company's current offering, tirzepatide, has proven to be a strong contributor to Lilly's revenue, thanks to its dual hormone targeting that enhances weight loss and glycemic control. Marketed as Mounjaro for type 2 diabetes and Zepbound for obesity and certain forms of sleep apnea, tirzepatide remains a significant part of Lilly’s sales portfolio.
Lilly's next-generation oral GLP-1 receptor agonist, Orforglipron, is currently in late-stage development for obesity treatment. After successfully completing Phase 3 trials, Orforglipron has shown approximately 12.4% average weight loss over 72 weeks, with significant improvements in cardiovascular risk markers and a mild-to-moderate gastrointestinal side effect profile. Lilly plans to file for FDA approval for Orforglipron by late 2025, with potential approval and market launch in 2026.
Orforglipron is projected to achieve blockbuster status by 2027, with estimated sales reaching about $14.1 billion by 2031. This oral alternative to injectables is expected to complement and eventually expand Lilly’s weight management portfolio, appealing to patients averse to injections. The strong clinical results and potential blockbuster sales forecast suggest investor optimism about future growth opportunities beyond tirzepatide's established success.
While Eli Lilly's shares experienced a significant drop in price after reporting its first-quarter results, the company's strong lineup of medicines and a rich pipeline, including 11 obesity candidates, offer promising prospects. The introduction of Orforglipron is anticipated to positively affect Eli Lilly’s market valuation by expanding its share in the growing obesity treatment market.
As of August 2025, the forward price-to-earnings ratio of Eli Lilly stands at 35.5, higher than the average for the healthcare sector (16). Despite this, some analysts view Lilly as a strong pick for income-seeking investors, particularly given its growth potential. Shares of Eli Lilly have slightly lagged the S&P 500 this year, but at current levels, the company looks like a buy. Lilly has been growing its revenue at a significantly faster rate than its peers in the industry.
The second-quarter results for Eli Lilly are due on Aug. 7. Investors will be keen to see if the company can turn around its recent performance and set the stage for a strong second half of the year. With the potential approval and market launch of Orforglipron on the horizon, the future looks bright for Eli Lilly in the obesity treatment market.
Read also:
- Weekly updates from the German federal parliament, Bundestag
- Why Opt for Renewable Energy: 5 Key Advantages
- Carpool lane residency: Apologies to electric vehicle drivers, it's about time for genuine carpools to claim the carpool lane privilege
- Trump boosts tariffs on India due to escalating Russian oil imports
